SYRHA

Syrha is a French biotechnology company dedicated to the development of next-generation immunotherapies utilizing CD8+ regulatory T cells (CD8+ Tregs). Founded as a spin-off from Inserm and the University of Nantes, the company focuses on harnessing the natural suppressive capabilities of these cells to address unmet needs in organ transplantation and autoimmune disorders. Their therapeutic strategy involves the induction or administration of specific CD8+ Treg populations to promote long-term immune tolerance. Syrha's pipeline is currently in the pre-clinical phase, supported by extensive academic research into the mechanisms of immune regulation. The company aims to provide targeted treatments that avoid the side effects associated with systemic immunosuppression.